Everest Organics Ltd Stock Price Today (NSE: EVERESTO)
Fundamental Score
Everest Organics Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Everest Organics Ltd share price today is ₹305.50, up +0.64% on NSE/BSE as of 3 August 2026. Everest Organics Ltd (EVERESTO) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹329.08 (Cr). The 52-week high for EVERESTO share price is ₹536.40 and the 52-week low is ₹197.00. At a P/E ratio of 59.29x, EVERESTO is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 7.63% and a debt-to-equity ratio of 0.66.
Everest Organics Ltd Share Price Chart — NSE/BSE Historical Performance
Everest Organics Ltd share price chart: 20.04% return over the past month. 52-week high ₹536.40, 52-week low ₹197.00.
Everest Organics Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹309.65 | ₹309.90 | ₹295.00 | ₹300.10 | 1.02K (Cr) | |
| ₹298.00 | ₹309.95 | ₹290.00 | ₹303.55 | 519.00 (Cr) | |
| ₹321.00 | ₹321.00 | ₹291.10 | ₹300.25 | 807.00 (Cr) | |
| ₹296.00 | ₹298.85 | ₹278.30 | ₹288.75 | 1.75K (Cr) | |
| ₹298.00 | ₹301.00 | ₹292.05 | ₹296.00 | 869.00 (Cr) | |
| ₹291.05 | ₹291.80 | ₹290.00 | ₹290.35 | 394.00 (Cr) | |
| ₹297.00 | ₹305.00 | ₹290.10 | ₹291.00 | 49.00 (Cr) | |
| ₹305.00 | ₹319.00 | ₹303.15 | ₹308.05 | 2.87K (Cr) | |
| ₹338.00 | ₹338.00 | ₹285.10 | ₹322.35 | 228.00 (Cr) | |
| ₹322.80 | ₹322.80 | ₹301.00 | ₹303.45 | 1.47K (Cr) |
Everest Organics Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹262.00 | ₹344.90 | ₹245.00 | ₹300.10 | +14.54% | |
| ₹277.00 | ₹278.80 | ₹217.00 | ₹249.65 | -9.87% | |
| ₹265.00 | ₹292.00 | ₹232.20 | ₹268.30 | +1.25% | |
| ₹221.70 | ₹287.50 | ₹209.00 | ₹272.15 | +22.76% | |
| ₹344.50 | ₹344.50 | ₹197.00 | ₹203.45 | -40.94% | |
| ₹429.60 | ₹434.00 | ₹281.20 | ₹362.65 | -15.58% | |
| ₹500.00 | ₹536.40 | ₹388.30 | ₹405.00 | -19.00% | |
| ₹424.20 | ₹517.00 | ₹404.00 | ₹505.80 | +19.24% | |
| ₹379.05 | ₹469.70 | ₹378.05 | ₹424.20 | +11.91% | |
| ₹420.00 | ₹425.35 | ₹371.10 | ₹391.90 | -6.69% | |
| ₹395.00 | ₹431.00 | ₹380.00 | ₹405.65 | +2.70% | |
| ₹320.50 | ₹417.00 | ₹301.50 | ₹394.60 | +23.12% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Everest Organics Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Everest Organics Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of EVERESTO across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Strong Revenue Growth (19.11%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Balanced Promoter Holding (59.60%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
10 factors identified
Below-Average Return on Equity (7.63%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Margin Pressure Concerns (4.85%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Premium Valuation Risk (P/E: 59.29x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Growth History (1.56% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-19.73% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-16.56% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (2.23x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-3.80 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.02%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Everest Organics Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Everest Organics Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Everest Organics LtdEverest Organic...Selected✓ EVERESTO • 524790 | 23/100 | ₹305.50₹306 | ₹329.08₹329.08 | 59.29Average 59.3 Average | 7.63%Poor 7.63% Poor | 11.99%Average 11.99% Average | 0.66Good 0.7 Good | -16.56%Poor -16.56% Poor | 1.56%Average 1.56% Average | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Everest Organics Ltd PE Ratio History
Historical price-to-earnings ratio for EVERESTO — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹0.17 | ₹301.05 | 1770.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Everest Organics Ltd Quarterly Performance
Latest quarterly metrics for EVERESTO — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
19.11%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-9.62%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
1.56%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-16.56%
Compounded annual net profit growth over 5 years
Everest Organics Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for EVERESTO — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Everest Organics Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Everest Organics Ltd (EVERESTO) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Everest Organics Ltd
About EVERESTO (Everest Organics Ltd)
Everest Organics Ltd is a dynamic pharmaceutical company rooted in the heart of Hyderabad, India. Since its establishment in 1993, the company has steadily grown to become a signif...icant player in the production and distribution of vital pharmaceutical components. Everest Organics focuses primarily on manufacturing and supplying high-quality active pharmaceutical ingredients (APIs) alongside essential pharmaceutical intermediates. These crucial building blocks are the foundation upon which numerous life-saving medications are built, highlighting the company's commitment to contributing to global healthcare solutions. With a strong emphasis on quality control and adherence to stringent regulatory standards, Everest Organics ensures that its products meet the exacting demands of the pharmaceutical industry. Beyond its domestic operations, Everest Organics is actively engaged in exporting its meticulously crafted products to international markets. This global reach demonstrates the company's dedication to serving a wider audience and solidifying its position as a reliable source for pharmaceutical ingredients worldwide. By expanding its export capabilities, Everest Organics strengthens its business resilience and contributes to the accessibility of essential medications across borders. The company's commitment to international trade reflects its ambition to be a globally recognized leader in the pharmaceutical manufacturing sector, while upholding the highest ethical and quality standards in all its operations. Everest Organics' core business revolves around the production of bulk drugs and their related components, reflecting its strategic focus on the upstream pharmaceutical supply chain. This specialized area allows the company to leverage its expertise in chemical synthesis and manufacturing processes to create highly purified and effective pharmaceutical ingredients. By concentrating on bulk drug manufacturing, Everest Organics plays a vital role in enabling pharmaceutical companies to efficiently and reliably produce finished medications. The company's commitment to continuous improvement and innovation ensures that its manufacturing capabilities remain at the forefront of the industry, further solidifying its position as a trusted partner in the pharmaceutical ecosystem.
Company Details
Key Leadership
Corporate Events
Latest News
EVERESTO Share Price: Frequently Asked Questions
What is the current share price of Everest Organics Ltd?
Everest Organics Ltd (EVERESTO) trades at ₹305.50 on NSE and BSE. Market cap ₹329.08 (Cr). Educational data only.
What is the P/E ratio of Everest Organics Ltd?
Everest Organics Ltd has a P/E of 59.29x vs industry average 34.89x.
What is the Bull Run score for Everest Organics Ltd?
Everest Organics Ltd has a Bull Run score of 23/100 based on 25+ financial parameters.
Does Everest Organics Ltd pay dividends?
Everest Organics Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Everest Organics Ltd?
Everest Organics Ltd has ROE of 7.63%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Everest Organics Ltd?
Everest Organics Ltd has debt-to-equity of 0.66.
Is Everest Organics Ltd a good investment?
Bull Run gives Everest Organics Ltd a score of 23/100. This is not investment advice — consult a SEBI-registered advisor.